Clinical Genetics · Great Neck, NY
NPI
1922412295
Since 2014
Specialty
Clinical Genetics
Code 207SG0201X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
225 Community Dr
Great Neck, NY, 11021
Phone (516) 918-4800
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,453
59 services
Medicare patients, 2024
30
Average age 61
Drug cost, 2024
$4.7M
153 prescriptions
Company payments, 2025
$117
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jessica Gold was code 99215 (office e&m - established), 22 times for 13 patients. In total Jessica Gold billed 59 services in 7 codes, and Medicare paid $6,453.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 22 | 13 | $152.41 | $3,353 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 18 | 12 | $14.52 | $261 |
| 99205 Office E&M - New | Office | 15 | 15 | $166.75 | $2,501 |
Medicare prescription drug claims, 2024
In 2024, the drug Jessica Gold prescribed most often to Medicare patients was Nexviazyme (Avalglucosidase Alfa-Ngpt), with 62 prescriptions and refills. In total Jessica Gold wrote 153 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Nexviazyme Avalglucosidase Alfa-Ngpt | 62 | 62 | Under 11 | $1.9M |
| Dextrose In Water Dextrose 5 % In Water | 41 | 41 | Under 11 | $255 |
| Elaprase Idursulfase | 14 | 14 | Under 11 | $1.8M |
| Lumizyme Alglucosidase Alfa | 13 | 13 | Under 11 | $611K |
Brand drugs: 138 claims; generic drugs: 15 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jessica Gold $117 ($117 in general payments such as food, travel and fees) from 2 companies. The largest payer was Orchard Therapeutics North America with $117.
| Company | Payments | Amount |
|---|---|---|
| Orchard Therapeutics North America | 1 | $117 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.